{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014426","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.777720+00:00","generated_at":"2026-06-24T03:55:21.101122+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biodesix Q2 core lung diag revenue $7.3M (+52% YoY); net loss $15.8M; reaffirms 2022 guidance","bullets":["Core lung diagnostic revenue $7.3M, up 52% YoY; total revenue $11.0M down 8% due to COVID test decline.","Net loss $15.8M, up 39% driven by loss on extinguishment from Indi contingent consideration restructuring.","Cash and equivalents $28.7M (incl. $5.1M restricted); raised net $27.3M in debt/equity during Q2.","Reaffirmed 2022 revenue outlook of $37.5M-$39.5M; Medicare coverage secured for Nodify CDT test.","Announced strategic pacts with Philips, MSK, and Bio-Rad to co-develop an MRD test for solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014426","json":"https://secwatch.observer/filing/0000950170-22-014426.json","markdown":"https://secwatch.observer/filing/0000950170-22-014426.md","text":"https://secwatch.observer/filing/0000950170-22-014426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022014426/0000950170-22-014426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022014426/bdsx-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:55:21.101122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}